In our recent publication, the Ingress-Health RWE team, together with clinical experts, analyzed a big German claims dataset with >8 million insured to explore unmet needs in patients with Inflammatory Bowel disease not treated with biologics. The team identified a substantial percentage of patients who suffer from active disease and/or steroid dependency, and the majority
According to the World Health Organization (WHO), 235 million people suffer from asthma worldwide. To learn more about potential barriers to therapy adherence in asthma, click here
Ingress-health B.V. and Indivumed GmbH announced today the launch of an exclusive partnership on real-world evidence (RWE) studies in oncology. Click here to find out more!
Lung cancer is the leading cause of cancer-associated mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for a majority of the reported cases. Ingress-health recently conducted a German claims data analysis to assess the real-world treatment of patients with NSCLC. Click here to find out more!
World Cancer Day empowers everyone around the world to show support, raise our collective voice and take action. We, at Ingress-Health, believe that there is a significant need to collect and analyze RWE to demonstrate drug effectiveness in clinical practice. Therefore, we developed a framework to use RWE along with clinical trial efficacy data to
Ingress-health is constantly eager to explore methods and frameworks for conducting patient preference research. In a recent study, the impact of the design of a discrete choice experiment on its results was analyzed. To find out more about this, check out our ISPOR poster. Click here to find out more.
This month, Ingress-health team participated in 2 posters being presented at the Transplantation & Cellular Therapy (TCT) Meetings of ASBMT and CIBMTR in Houston, Texas. Based on systematic literature reviews, the research focused on the survival of relapsed/ refractory patients with acute myeloid leukemia (AML) who underwent stem cell transplantation (SCT) after salvage therapy. A
On Monday, the International Epilepsy Day promoted awareness about the 50 million people living with epilepsy worldwide. To commemorate this day, we have shared a poster of a recent study by our team in which incidence and treatment of patients with status epilepticus were analyzed in Germany using claims database. To learn more about the
It is cervical cancer awareness prevention week in the UK. Did you know that Ingress-health is strongly focused on conducting research in oncology? We recently conducted an epidemiological analysis based on claims data of more than 2.9 million insured persons to analyze prevalence and incidence of cancers in Germany. Click here to have a look
ABQ-HIV: a unique questionnaire for identifying potential risk factors associated with medication related non-adherence for HIV-patients Non-adherence to medication is a major challenge in the real-life treatment of chronically ill patients. Therefore, our team has developed a questionnaire (“Adherence Barriers Questionnaire“ – ABQ) which successfully identifies patient-specific adherence barriers and offers patient segmentation for individual